AVLO news

Avalo Therapeutics' board established a new series of preferred stock with an initial stated value of $5,796.93 per share, convertible to common stock. The offering is led by Commodore Capital Master LP and provides the company with additional capital financing options.

Avalo Therapeutics' Board of Directors adopted and stockholders approved an amended Employee Stock Purchase Plan on June 2, 2026, allowing eligible employees to purchase company shares. The plan modification reflects standard corporate governance practices for employee compensation and retention.